# Marea Therapeutics

> Marea Therapeutics is a clinical-stage biotechnology company in San Francisco developing first-in-class medicines for cardioendocrine and cardiometabolic diseases. Incubated by Third Rock Ventures and led by Dr. Josh Lehrer, Marea uses human genetics insights to drive its pipeline, headlined by MAR001, an ANGPTL4-targeting antibody aimed at residual cardiovascular risk, and MAR002 for acromegaly.

- **Founded:** 2023
- **Headquarters:** San Francisco, United States
- **Founders:** Ethan Weiss (Co-founder, Chief Scientific Officer), Charles Homcy (Co-founder, Third Rock Ventures), Stephen O'Rahilly (Scientific Co-founder, University of Cambridge), Joshua Rabinowitz (Scientific Co-founder, Princeton University)
- **Team size:** 39
- **Products:** MAR001, MAR002, Pipeline programs
- **Notable:** Launched in June 2024 with a $190M combined Series A/B financing., Reported Phase 1b data showing MAR001 reduced remnant cholesterol, supporting advance into Phase 2b., Positive Phase 1 topline data for MAR002 in acromegaly.

## Products & services

- **MAR001** — First-in-class subcutaneous monoclonal antibody targeting ANGPTL4 to lower remnant cholesterol and address residual cardiovascular risk. In Phase 2 development.
- **MAR002** — Long-acting antibody candidate for acromegaly. Reported positive Phase 1 topline data with potential best-in-disease efficacy and dosing profile.
- **Pipeline programs** — Earlier-stage cardioendocrine programs driven by human genetics validation.

## Achievements

- Launched in June 2024 with a $190M combined Series A/B financing.
- Reported Phase 1b data showing MAR001 reduced remnant cholesterol, supporting advance into Phase 2b.
- Positive Phase 1 topline data for MAR002 in acromegaly.
- Named on a Best Places to Work list by the San Francisco Business Times (2025).

## Latest updates

- **2024-06** — Marea launches publicly with $190M combined Series A/B funding led by Sofinnova for Series B.
- **2024-12** — Expanded management team and board of directors.
- **2025** — Positive Phase 1b readout for MAR001 in remnant cholesterol; advancing to Phase 2b.
- **2025** — Positive Phase 1 topline data for MAR002 in acromegaly.

## Links

- Website: https://mareatx.com
- LinkedIn: https://www.linkedin.com/company/marea-therapeutics
- Twitter/X: https://twitter.com/Marea_tx

---

Profile page: https://yespress.io/marea-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-28